Business, energy, technology, markets and global industry news from Business News Today

Lundbeck

PharmaDeviceNews Lundbeck
Representative image: A neurology consultation scene highlights the growing clinical focus on migraine prevention as Lundbeck’s bocunebart Phase IIb data strengthen interest in PACAP-targeted therapies for patients with hard-to-treat migraine.
Pharma & Biotech

Why Lundbeck’s anti-PACAP migraine drug could matter beyond another Phase II win

Find out how Lundbeck’s bocunebart Phase IIb data could reshape migraine prevention and test the PACAP pathway.

Read More
Pharma & Biotech

Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured

Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.

Read More